Silencing hsp25/hsp27 gene expression augments proteasome activity and increases CD8 + T-cell-mediated tumor killing and memory responses

Cancer Prevention Research

Volumn 5, Issue 1, 2012, Pages 122-137

  Nagaraja, Ganachari M ^a   Kaur, Punit ^a   Neumann, William ^a   Asea, Edwina E ^a   Bausero, Mariá A ^b   Multhoff, Gabriele ^c   Asea, Alexzander ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b INSTITUT PASTEUR DE MONTEVIDEO   (Uruguay)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN 25; HEAT SHOCK PROTEIN 27; MESSENGER RNA; PROTEASOME; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; BREAST TUMOR; CD8+ T LYMPHOCYTE; CELL KILLING; CELL TRANSFER; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOLOGICAL MEMORY; LENTIVIRINAE; MEMORY CELL; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; RNA INTERFERENCE; TUMOR CELL; TUMOR VOLUME;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; HSP27 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOLOGIC MEMORY; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 84855546696     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0121     Document Type: Article

References (48)

1. Oesterreich S, Hickey E, Weber LA, Fuqua SA. Basal regulatory promoter elements of the hsp27 gene in human breast cancer cells. Biochem Biophys Res Commun 1996;222:155-63. (Pubitemid 26152221)
2. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74. (Pubitemid 37328786)
3. Soldes OS, Kuick RD, Thompson IA II, Hughes SJ, Orringer MB, Iannettoni MD, et al. Differential expression of Hsp27 in normal oesophagus, Barrett's metaplasia and oesophageal adenocarcinomas. Br J Cancer 1999;79:595-603.
4. Budhram-Mahadeo VS, Heads RJ. Heat shock protein-27 (hsp27) in breast cancers: regulation of expression and function. In: Calderwood SK, Sherman MY, Ciocca DR, editors. Heat shock proteins in cancer. Dordrecht, The Netherlands: Springer; 2007. p. 93-130.
5. O'Neill PA, Shaaban AM, West CR, Dodson A, Jarvis C, Moore P, et al. Increased risk of malignant progression in benign proliferating breast lesions defined by expression of heat shock protein 27. Br J Cancer 2004;90:182-8. (Pubitemid 38174959)
6. Rust W, Kingsley K, Petnicki T, Padmanabhan S, Carper SW, Plopper GE. Heat shock protein 27 plays two distinct roles in controlling human breast cancer cell migration on laminin-5. Mol Cell Biol Res Commun 1999;1:196-202. (Pubitemid 129532303)
7. Ciocca DR, Lo Castro G, Alonio LV, Cobo MF, Lotfi H, Teyssie A. Effect of human papillomavirus infection on estrogen receptor and heat shock protein hsp27 phenotype in human cervix and vagina. Int J Gynecol Pathol 1992;11:113-21.
8. Oesterreich S, Weng CN, Qiu M, Hilsenbeck SG, Osborne CK, Fuqua SA. The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res 1993;53:4443-8. (Pubitemid 23304358)
9. Yamamoto K, Okamoto A, Isonishi S, Ochiai K, Ohtake Y. Heat shock protein 27 was up-regulated in cisplatin resistant human ovarian tumor cell line and associated with the cisplatin resistance. Cancer Lett 2001;168:173-81. (Pubitemid 32524279)
10. Storm FK, Mahvi DM, Gilchrist KW. Heat shock protein 27 overexpression in breast cancer lymph node metastasis. Ann Surg Oncol 1996;3:570-3. (Pubitemid 126729008)
11. Thor A, Benz C, Moore D II, Goldman E, Edgerton S, Landry J, et al. Stress response protein (srp-27) determination in primary human breast carcinomas: clinical, histologic, and prognostic correlations. J Natl Cancer Inst 1991;83:170-8.
12. Vargas-Roig LM, Gago FE, Tello O, Aznar JC, Ciocca DR. Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 1998;79:468-75. (Pubitemid 28445267)
13. Sondel PM, Rakhmilevich AL, de Jong JLO, Hank JA. Cellular immunity and cytokines. In: Mendelsohn J, Howley PM, Israel MA, Liotta LA, editors. The molecular basis of cancer. Philadelphia, PA: W.B. Saunders; 2001. p. 535-71.
14. Kloetzel PM. The proteasome and MHC class I antigen processing. Biochim Biophys Acta 2004;1695:225-33.
15. Groettrup M, Soza A, Eggers M, Kuehn L, Dick TP, Schild H, et al. A role for the proteasome regulator PA28alpha in antigen presentation. Nature 1996;381:166-8.
16. Dick TP, Ruppert T, Groettrup M, Kloetzel PM, Kuehn L, Koszinowski UH, et al. Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands. Cell 1996;86:253-62. (Pubitemid 26286108)
17. Sun Y, Sijts AJ, Song M, Janek K, Nussbaum AK, Kral S, et al. Expression of the proteasome activator PA28 rescues the presentation of a cytotoxic T lymphocyte epitope on melanoma cells. Cancer Res 2002;62:2875-82. (Pubitemid 34525774)
18. Stohwasser R, Salzmann U, Giesebrecht J, Kloetzel PM, Holzhutter HG. Kinetic evidences for facilitation of peptide channelling by the proteasome activator PA28. Eur J Biochem 2000;267:6221-30.
19. Whitby FG, Masters EI, Kramer L, Knowlton JR, Yao Y, Wang CC, et al. Structural basis for the activation of 20S proteasomes by 11S regulators. Nature 2000;408:115-20.
20. Pamer E, Cresswell P. Mechanisms of MHC class I-restricted antigen processing. Annu Rev Immunol 1998;16:323-58. (Pubitemid 28183368)
21. Chauhan D, Li G, Shringarpure R, Podar K, Ohtake Y, Hideshima T, et al. Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 2003;63:6174-7. (Pubitemid 37255160)
22. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002;99:14374-9. (Pubitemid 35257679)
23. Andrieu C, Taieb D, Baylot V, Ettinger S, Soubeyran P, De-Thonel A, et al. Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E. Oncogene 2010;29:1883-96.
24. Trott D, McManus CA, Martin JL, Brennan B, Dunn MJ, Rose ML. Effect of phosphorylated hsp27 on proliferation of human endothelial and smooth muscle cells. Proteomics 2009;9:3383-94.
25. Knapinska AM, Gratacos FM, Krause CD, Hernandez K, Jensen AG, Bradley JJ, et al. Chaperone Hsp27 modulates AUF1 proteolysis and AU-rich element-mediated mRNA degradation. Mol Cell Biol 2011;31:1419-31.
26. Chang E, Heo KS, Woo CH, Lee H, Le NT, Thomas TN, et al. MK2 SUMOylation regulates actin filament remodeling and subsequent migration in endothelial cells by inhibiting MK2 kinase and HSP27 phosphorylation. Blood 2011;117:2527-37.
27. de Thonel A, Vandekerckhove J, Lanneau D, Selvakumar S, Courtois G, Hazoume A, et al. HSP27 controls GATA-1 protein level during erythroid cell differentiation. Blood 2010;116:85-96.
28. Parcellier A, Brunet M, Schmitt E, Col E, Didelot C, Hammann A, et al. HSP27 favors ubiquitination and proteasomal degradation of p27Kip1 and helps S-phase re-entry in stressed cells. FASEB J 2006;20:1179-81.
29. Parcellier A, Schmitt E, Gurbuxani S, Seigneurin-Berny D, Pance A, Chantome A, et al. HSP27 is a ubiquitin-binding protein involved in I-kappaBalpha proteasomal degradation. Mol Cell Biol 2003;23:5790-802. (Pubitemid 36951341)
30. Friant S, Meier KD, Riezman H. Increased ubiquitin-dependent degradation can replace the essential requirement for heat shock protein induction. EMBO J 2003;22:3783-91. (Pubitemid 36975707)
31. den Engelsman J, Keijsers V, de Jong WW, Boelens WC. The small heat-shock protein alpha B-crystallin promotes FBX4-dependent ubiquitination. J Biol Chem 2003;278:4699-704. (Pubitemid 36800969)
32. Guay J, Lambert H, Gingras-Breton G, Lavoie JN, Huot J, Landry J. Regulation of actin filament dynamics by p38 map kinase-mediated phosphorylation of heat shock protein 27. J Cell Sci 1997;110:357-68. (Pubitemid 27095655)
33. Yu YY, George T, Dorfman JR, Roland J, Kumar V, Bennett M. The role of Ly49A and 5E6(Ly49C) molecules in hybrid resistance mediated by murine natural killer cells against normal T cell blasts. Immunity 1996;4:67-76. (Pubitemid 26054937)
34. Koh CY, Blazar BR, George T, Welniak LA, Capitini CM, Raziuddin A, et al. Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood 2001;97:3132-7.
35. Farooqui-Kabir SR, Budhram-Mahadeo V, Lewis H, Latchman DS, Marber MS, Heads RJ. Regulation of Hsp27 expression and cell survival by the POU transcription factor Brn3a. Cell Death Differ 2004;11:1242-4. (Pubitemid 39529967)
36. Rocchi P, Beraldi E, Ettinger S, Fazli L, Vessella RL, Nelson C, et al. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res 2005;65:11083-93. (Pubitemid 41713379)
37. Rocchi P, Jugpal P, So A, Sinneman S, Ettinger S, Fazli L, et al. Small interferenceRNAtargeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro. BJU Int 2006;98:1082-9. (Pubitemid 44536463)
38. Farkas B, Hantschel M, Magyarlaki M, Becker B, Scherer K, Landthaler M, et al. Heat shock protein 70 membrane expression and melanoma-associated marker phenotype in primary and metastatic melanoma. Melanoma Res 2003;13:147-52. (Pubitemid 36583976)
39. Gehrmann M, Schmetzer H, Eissner G, Haferlach T, Hiddemann W, Multhoff G. Membrane-bound heat shock protein 70 (Hsp70) in acutemyeloid leukemia: a tumor specific recognition structure for the cytolytic activity of autologous NK cells. Haematologica 2003;88:474-6. (Pubitemid 36547137)
40. Kleinjung T, Arndt O, Feldmann HJ, Bockmuhl U, Gehrmann M, Zilch T, et al. Heat shock protein 70 (Hsp70) membrane expression on head-and- neck cancer biopsy-a target for natural killer (NK) cells. Int J Radiat Oncol Biol Phys 2003;57:820-6. (Pubitemid 37194310)
41. Gross C, Holler E, Stangl S, Dickinson A, Pockley AG, AseaAA, et al. An Hsp70 peptide initiates NK cell killing of leukemic blasts after stem cell transplantation. Leuk Res 2008;32:527-34. (Pubitemid 351248951)
42. Stangl S, Gross C, Pockley AG, Asea AA, Multhoff G. Influence of Hsp70 and HLA-E on the killing of leukemic blasts by cytokine/Hsp70 peptide-activated human natural killer (NK) cells. Cell Stress Chaperones 2008;13:221-30.
43. Stangl S, Gehrmann M, Dressel R, Alves F, Dullin C, Themelis G, et al. In vivo imaging of CT26 mouse tumours by using cmHsp70.1 monoclonal antibody. J Cell Mol Med 2011;15:874-87.
44. Stangl S, Gehrmann M, Riegger J, Kuhs K, Riederer I, Sievert W, et al. Targeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody. Proc Natl Acad Sci U S A 2011;108:733-8.
45. DeVincenzo J, Lambkin-Williams R, Wilkinson T, Cehelsky J, Nochur S, Walsh E, et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A 2010;107:8800-5.
46. Leachman SA, Hickerson RP, Schwartz ME, Bullough EE, Hutcherson SL, Boucher KM, et al. First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther 2010;18:442-6.
47. Kaiser PK, Symons RC, Shah SM, Quinlan EJ, Tabandeh H, Do DV, et al. RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. Am J Ophthalmol 2010;150:33-9.e2.
48. Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 2010;9:57-67.